S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Price, News & Analysis

$6.60
-0.14 (-2.08%)
(As of 03/28/2024 ET)
Today's Range
$6.51
$6.76
50-Day Range
$5.01
$6.74
52-Week Range
$3.06
$6.76
Volume
5.26 million shs
Average Volume
3.40 million shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.88

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
19.3% Upside
$7.88 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of ADMA Biologics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$3.93 M Sold Last Quarter
Proj. Earnings Growth
66.67%
From $0.30 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

446th out of 939 stocks

Biological Products, Except Diagnostic Industry

71st out of 158 stocks

ADMA stock logo

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

ADMA Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
ADMA Biologics (NASDAQ:ADMA) Reaches New 12-Month High at $6.69
ADMA Biologics' (ADMA) "Buy" Rating Reaffirmed at HC Wainwright
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
ADMA Biologics (NASDAQ:ADMA) Shares Up 3.2%
ADMA Biologics (NASDAQ:ADMA) Hits New 1-Year High at $6.44
ADMA Biologics (NASDAQ:ADMA) Sets New 12-Month High at $6.44
ADMA Apr 2024 5.000 put
Q4 2023 ADMA Biologics Inc Earnings Call
ADMA Biologics, Inc.: ADMA Biologics Announces CFO Transition
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
ADMA Biologics' CFO to step down
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMA
Employees
624
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.88
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+19.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-28,240,000.00
Pretax Margin
-10.94%

Debt

Sales & Book Value

Annual Sales
$258.21 million
Cash Flow
$0.05 per share
Book Value
$0.60 per share

Miscellaneous

Free Float
214,527,000
Market Cap
$1.51 billion
Optionable
Optionable
Beta
0.43
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


ADMA Stock Analysis - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price target for 2024?

4 analysts have issued 12-month target prices for ADMA Biologics' shares. Their ADMA share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $7.88 in the next year. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2024?

ADMA Biologics' stock was trading at $4.52 at the beginning of 2024. Since then, ADMA stock has increased by 46.0% and is now trading at $6.60.
View the best growth stocks for 2024 here
.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 7,990,000 shares, an increase of 18.9% from the February 29th total of 6,720,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the days-to-cover ratio is currently 3.0 days.
View ADMA Biologics' Short Interest
.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ADMA earnings forecast
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%.

What ETF holds ADMA Biologics' stock?

Virtus LifeSci Biotech Products ETF holds 88,335 shares of ADMA stock, representing 1.90% of its portfolio.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.0 million-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.71%), Vanguard Group Inc. (5.65%), Nuveen Asset Management LLC (5.03%), Stonepine Capital Management LLC (4.08%), Perceptive Advisors LLC (2.85%) and Assenagon Asset Management S.A. (1.75%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon.
View institutional ownership trends
.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADMA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners